SPPI Spectrum Pharmaceuticals Inc.

8.01
+0.59  (+8%)
Previous Close 7.42
Open 7.49
Price To Book 3.54
Market Cap 903,973,813
Shares 112,855,657
Volume 586,067
Short Ratio
Av. Daily Volume 779,819

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 top-line data from Cohort 1 due 4Q 2019. Cohort 2 data due mid-2020.
Poziotinib
Non-small cell lung cancer (NSCLC) with exon 20 insertion mutation in EGFR or HER2
Phase 2 initiation announced March 30, 2017 with preliminary data released October 18, 2017 - ORR 73%.
Poziotinib
Non-small cell lung cancer (NSCLC)
CRL received October 9, 2009. Approved April 29, 2011.
FUSILEV
Colorectal cancer
CRL received July 5, 2009.
ZEVALIN
Non-Hodgkin’s lymphoma
CRL October 23 2015. Approved March 15 2016.
EVOMELA (melphalan) for Injection
Conditioning treatment prior to autologous stem cell transplant for patients with multiple myeloma
Failed to meet primary endpoint in Phase 3 trial - Apr 2012. PDUFA date December 11 2016. Advisory Committee Meeting September 14 2016 voted 14 - 0 against approval. CRL issued November 17, 2016. New Phase 3 trial initiation announced August 14, 2017.
QAPZOLA - Apaziquone
Bladder cancer
BLA to be refiled 4Q 2019.
SPI-2012 (ROLONTIS)
Chemotherapy-Induced Neutropenia
Approved July 7, 2014.
Belinostat
Peripheral T-Cell Lymphoma cancer
Phase 2 data at ASH December 2018.
Leucovorin
Peripheral T-Cell Lymphoma cancer

Latest News

  1. How Much Are Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) Insiders Taking Off The Table?
  2. Rockville biopharma to sell first product on market in 28 years — but not in the U.S.
  3. Spectrum Pharma's (SPPI) Loss Narrows in Q2, Stock Rises
  4. Edited Transcript of SPPI earnings conference call or presentation 8-Aug-19 8:30pm GMT
  5. Spectrum Pharmaceuticals, Inc. (SPPI) Q2 2019 Earnings Call Transcript
  6. Spectrum Pharmaceuticals (SPPI) Reports Q2 Loss, Misses Revenue Estimates
  7. Spectrum Pharmaceuticals Reports Second Quarter 2019 Financial Results and Pipeline Update
  8. Analysts Estimate Spectrum Pharmaceuticals (SPPI) to Report a Decline in Earnings: What to Look Out for
  9. Spectrum Announces Expansion of the Poziotinib Clinical Program
  10. Here’s What Hedge Funds Think About Spectrum Pharmaceuticals, Inc. (SPPI)
  11. The 5 Most Expensive Drugs In US: What You Should Know
  12. Spectrum Pharmaceuticals Appoints Elizabeth Czerepak to its Board of Directors
  13. What Kind Of Investor Owns Most Of Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI)?
  14. Ligand Inks Oncology Drug Discovery Deal With PhoreMost
  15. Why Is Spectrum Pharma (SPPI) Down 14.4% Since Last Earnings Report?
  16. Spectrum Pharmaceuticals Announces Integrated Results from Two Phase 3 ROLONTIS® (eflapegrastim) Trials Being Presented at the ASCO Annual Meeting
  17. Spectrum Pharmaceuticals to Present Corporate Update at the Jefferies 2019 Global Healthcare Conference on June 5th
  18. Spectrum Announces Poziotinib ZENITH20 Trial HER2 Cohort (Cohort 2) Has Reached Enrollment Target
  19. Edited Transcript of SPPI earnings conference call or presentation 9-May-19 8:30pm GMT
  20. Spectrum Pharmaceuticals to Present Corporate Update at the 20th Annual B. Riley FBR Investor Conference on May 23rd